Anbio Biotechnology Class A Ordinary Shares(NNNN)Earnings, Financials & Key Ratios
NNNN•NASDAQ
$29.20
$1.28B mkt cap·521.4× P/E·Price updated May 6, 2026
AboutAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.Show more
- Revenue$8M+21.9%
- EBITDA$3M+30.0%
- Net Income$2M+5.3%
- EPS (Diluted)0.06+366.7%
- Gross Margin71.9%+43.6%
- EBITDA Margin31.36%+6.6%
- Operating Margin24.38%-16.6%
- Net Margin28.99%-13.7%
- ROE14.83%-10.0%
- ROIC28.34%+1.9%
NNNN Key Insights
Anbio Biotechnology Class A Ordinary Shares (NNNN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 54.7%
- ✓FCF machine: 25.4% free cash flow margin
- ✓Share count reduced 77.5% through buybacks
- ✓Healthy 5Y average net margin of 40.6%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 71.8x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NNNN Price & Volume
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock price & volume — 10-year historical chart
Loading chart...
NNNN Growth Metrics
Anbio Biotechnology Class A Ordinary Shares (NNNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years22.72%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-2.19%
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years30.15%
TTM-
Return on Capital
10 Years64.71%
5 Years64.71%
3 Years54%
Last Year12.47%
NNNN Peer Comparison
Anbio Biotechnology Class A Ordinary Shares (NNNN) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CLOV | 1.35B | 2.61 | -15.35 | 40.34% | -4.45% | -27.71% | ||
 ACHC | 2.33B | 25.27 | -2.08 | 5.04% | -32.84% | -40.92% | 1.24 | |
 QDEL | 793.83M | 11.66 | -0.70 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CHEK | 12.17M | 2.08 | -0.48 | -226.19% | ||||
 IDXX | 44.83B | 562.97 | 43.04 | 10.42% | 24.63% | 70.87% | 2.35% | 0.67 |
 BIO | 6.94B | 257.12 | 9.23 | 0.65% | 6.52% | 2.4% | 5.4% | 0.21 |
 NEOG | 2.02B | 9.27 | -1.84 | -3.2% | -68.47% | -28.64% | 0.44 | |
 ALGN | 12.08B | 168.71 | 29.86 | 0.9% | 10.5% | 10.7% | 4.06% | 0.03 |
Compare NNNN vs Peers
Anbio Biotechnology Class A Ordinary Shares (NNNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NNNN Income Statement
Anbio Biotechnology Class A Ordinary Shares (NNNN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
| Sales/Revenue | 4.43M | 23.54M | 6.71M | 8.19M |
| Revenue Growth % | - | 431.67% | -71.49% | 21.95% |
| Cost of Goods Sold | 1.89M | 10.98M | 3.35M | 2.3M |
| COGS % of Revenue | 42.6% | 46.64% | 49.93% | 28.1% |
| Gross Profit | 2.54M▲ 0% | 12.56M▲ 394.3% | 3.36M▼ 73.2% | 5.89M▲ 75.1% |
| Gross Margin % | 57.4% | 53.36% | 50.07% | 71.9% |
| Gross Profit Growth % | - | 394.25% | -73.25% | 75.11% |
| Operating Expenses | 86.09K | 2.37M | 1.4M | 3.89M |
| OpEx % of Revenue | 1.94% | 10.06% | 20.86% | 47.53% |
| Selling, General & Admin | 86.09K | 2.17M | 1.27M | 3.44M |
| SG&A % of Revenue | 1.94% | 9.21% | 18.85% | 41.98% |
| Research & Development | 0 | 200K | 134.7K | 454.23K |
| R&D % of Revenue | - | 0.85% | 2.01% | 5.55% |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | 2.46M▲ 0% | 10.2M▲ 315.2% | 1.96M▼ 80.8% | 2M▲ 1.8% |
| Operating Margin % | 55.46% | 43.3% | 29.22% | 24.38% |
| Operating Income Growth % | - | 315.15% | -80.77% | 1.76% |
| EBITDA | 2.54M | 10.2M | 1.97M | 2.57M |
| EBITDA Margin % | 57.26% | 43.33% | 29.41% | 31.36% |
| EBITDA Growth % | - | 302.31% | -80.65% | 30.03% |
| D&A (Non-Cash Add-back) | 0 | 6.25K | 13.04K | 0 |
| EBIT | 2.54M | 10.02M | 2.25M | 2.37M |
| Net Interest Income | 0 | 34.25K | 165.34K | 337.51K |
| Interest Income | 0 | 42.24K | 165.34K | 337.51K |
| Interest Expense | 0 | 8K | 0 | 0 |
| Other Income/Expense | 79.94K | -184.41K | 292.78K | 377.48K |
| Pretax Income | 2.54M▲ 0% | 10.01M▲ 294.8% | 2.25M▼ 77.5% | 2.37M▲ 5.3% |
| Pretax Margin % | 57.26% | 42.52% | 33.58% | 28.99% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | 2.54M▲ 0% | 10.01M▲ 294.8% | 2.25M▼ 77.5% | 2.37M▲ 5.3% |
| Net Margin % | 57.26% | 42.52% | 33.58% | 28.99% |
| Net Income Growth % | - | 294.79% | -77.49% | 5.29% |
| Net Income (Continuing) | 2.54M | 10.01M | 2.25M | 2.37M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.03▲ 0% | 0.07▲ 174.0% | 0.01▼ 82.8% | 0.06▲ 366.7% |
| EPS Growth % | - | 174.02% | -82.76% | 366.67% |
| EPS (Basic) | 0.03 | 0.07 | 0.02 | 0.06 |
| Diluted Shares Outstanding | 100M | 143.89M | 187.78M | 42.29M |
| Basic Shares Outstanding | 100M | 143.89M | 143.89M | 42.29M |
| Dividend Payout Ratio | - | - | - | - |
NNNN Balance Sheet
Anbio Biotechnology Class A Ordinary Shares (NNNN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
| Total Current Assets | 4.92M | 13.94M | 15.75M | 18.53M |
| Cash & Short-Term Investments | 4.18M | 8.67M | 9.69M | 11.76M |
| Cash Only | 4.18M | 7.1M | 9.69M | 11.76M |
| Short-Term Investments | 0 | 1.57M | 0 | 0 |
| Accounts Receivable | 717.5K | 3.58K | 1.88M | 1.06M |
| Days Sales Outstanding | 59.14 | 0.06 | 102.5 | 47.48 |
| Inventory | 0 | 353.87K | 0 | 0 |
| Days Inventory Outstanding | - | 11.76 | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 0 | 15.05K | 62.14K | 387.44K |
| Property, Plant & Equipment | 0 | 12.06K | 0 | 0 |
| Fixed Asset Turnover | - | 1952.45x | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 2.99K | 62.14K | 387.44K |
| Total Assets | 4.92M▲ 0% | 13.96M▲ 184.0% | 15.81M▲ 13.3% | 18.92M▲ 19.7% |
| Asset Turnover | 0.90x | 1.69x | 0.42x | 0.43x |
| Asset Growth % | - | 183.95% | 13.28% | 19.67% |
| Total Current Liabilities | 2.38M | 1.41M | 993.06K | 1.73M |
| Accounts Payable | 1.89M | 1.41M | 827.15K | 1.63M |
| Days Payables Outstanding | 365.65 | 46.8 | 90.09 | 257.95 |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 490K | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 |
| Current Ratio | 2.07x | 9.88x | 15.86x | 10.71x |
| Quick Ratio | 2.07x | 9.63x | 15.86x | 10.71x |
| Cash Conversion Cycle | - | -34.98 | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.38M | 1.41M | 993.06K | 1.73M |
| Total Debt | 0 | 0 | 0 | 0 |
| Net Debt | -4.18M | -7.1M | -9.69M | -11.76M |
| Debt / Equity | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | -1.65x | -0.70x | -4.91x | -4.58x |
| Interest Coverage | - | 1274.61x | - | - |
| Total Equity | 2.54M▲ 0% | 12.55M▲ 394.8% | 14.82M▲ 18.1% | 17.19M▲ 16.0% |
| Equity Growth % | - | 394.79% | 18.11% | 16.01% |
| Book Value per Share | 0.03 | 0.09 | 0.08 | 0.41 |
| Total Shareholders' Equity | 2.54M | 12.55M | 14.82M | 17.19M |
| Common Stock | 0 | 0 | 14.23K | 14.23K |
| Retained Earnings | 2.54M | 12.55M | 14.8M | 17.17M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
NNNN Cash Flow Statement
Anbio Biotechnology Class A Ordinary Shares (NNNN) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
| Cash from Operations | 4.18M | 4.45M | 898.37K | 2.08M |
| Operating CF Margin % | 94.42% | 18.9% | 13.38% | 25.42% |
| Operating CF Growth % | - | 6.4% | -79.81% | 131.57% |
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M |
| Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -40.87K | -163.39K | -337.1K |
| Working Capital Changes | 1.65M | -5.53M | -1.2M | 44.65K |
| Change in Receivables | -717.5K | 717.5K | -1.88M | 820.17K |
| Change in Inventory | 0 | -353.87K | 353.87K | 0 |
| Change in Payables | 1.89M | -481.82K | -580.89K | 798.1K |
| Cash from Investing | 0 | -1.53M | 1.73M | 337.1K |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | 0% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 0 | -42.84K | -344.61K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -42.84K | -344.61K |
| Net Change in Cash | 4.18M▲ 0% | 2.92M▼ 30.1% | 2.59M▼ 11.5% | 2.07M▼ 19.8% |
| Free Cash Flow | 4.18M▲ 0% | 4.45M▲ 6.4% | 898.37K▼ 79.8% | 2.08M▲ 131.6% |
| FCF Margin % | 94.42% | 18.9% | 13.38% | 25.42% |
| FCF Growth % | - | 6.4% | -79.81% | 131.57% |
| FCF per Share | 0.04 | 0.03 | 0.00 | 0.05 |
| FCF Conversion (FCF/Net Income) | 1.65x | 0.44x | 0.40x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
NNNN Key Ratios
Anbio Biotechnology Class A Ordinary Shares (NNNN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | 100% | 132.75% | 16.47% | 14.83% |
| Return on Invested Capital (ROIC) | - | 402.54% | 27.81% | 28.34% |
| Gross Margin | 57.4% | 53.36% | 50.07% | 71.9% |
| Net Margin | 57.26% | 42.52% | 33.58% | 28.99% |
| Interest Coverage | - | 1274.61x | - | - |
| FCF Conversion | 1.65x | 0.44x | 0.40x | 0.88x |
| Revenue Growth | - | 431.67% | -71.49% | 21.95% |
NNNN Frequently Asked Questions
Anbio Biotechnology Class A Ordinary Shares (NNNN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Anbio Biotechnology Class A Ordinary Shares (NNNN) reported $16.1M in revenue for fiscal year 2024. This represents a 264% increase from $4.4M in 2021.
Anbio Biotechnology Class A Ordinary Shares (NNNN) grew revenue by 21.9% over the past year. This is strong growth.
Yes, Anbio Biotechnology Class A Ordinary Shares (NNNN) is profitable, generating $5.0M in net income for fiscal year 2024 (29.0% net margin).
Dividend & Returns
Anbio Biotechnology Class A Ordinary Shares (NNNN) has a return on equity (ROE) of 14.8%. This is reasonable for most industries.
Anbio Biotechnology Class A Ordinary Shares (NNNN) generated $3.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More NNNN
Anbio Biotechnology Class A Ordinary Shares (NNNN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates